몰레큘러 파트너스(MOLN)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $3.92 (-6.67%), 시가총액 $0.14B, 52주 최저~최고 $3.47 ~ $5.13.
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x co
몰레큘러 파트너스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
몰레큘러 파트너스의 현재 주가는 $3.92 (-6.67%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
몰레큘러 파트너스의 시가총액은 약 $0.14B입니다.
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pip